[go: up one dir, main page]

LV12768B - METHOD FOR IMMUNE IMMUNE REACTION TO THERAPEUTIC PROTEINS - Google Patents

METHOD FOR IMMUNE IMMUNE REACTION TO THERAPEUTIC PROTEINS Download PDF

Info

Publication number
LV12768B
LV12768B LVP-01-62A LV010062A LV12768B LV 12768 B LV12768 B LV 12768B LV 010062 A LV010062 A LV 010062A LV 12768 B LV12768 B LV 12768B
Authority
LV
Latvia
Prior art keywords
agent
composition
soluble form
antibody
hemostatic
Prior art date
Application number
LVP-01-62A
Other languages
Latvian (lv)
Other versions
LV12768A (en
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Original Assignee
Genetics Institute, Inc.
American Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc., American Red Cross filed Critical Genetics Institute, Inc.
Publication of LV12768A publication Critical patent/LV12768A/en
Publication of LV12768B publication Critical patent/LV12768B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for treating a hemostatic disorder using agents which promote hemostasis and agents which inhibit a costimulatory signal in a T cell are provided. The instant compositions and methods enable the treatment of hemostatic disorders using foreign therapeutic proteins, while downmodulating immune responses to the therapeutic proteins

Claims (35)

IZGUDROJUMA FORMULAINVENTION FORMULA 1. Kompozīcija, saturoša pirmo aģentu, kas stimulē hemostāzi un otro aģentu, kas inhibē kostimulējošo signālu T šūnā.A composition comprising a first agent that stimulates hemostasis and a second agent which inhibits a costimulatory signal in a T cell. 2. Kompozīcija saskaņā ar 1. punktu, kas papildus satur farmaceitiski pieņemamu nesēju.The composition of claim 1, further comprising a pharmaceutically acceptable carrier. 3. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir faktors VIII.The composition of claim 1, wherein the first agent is factor VIII. 4. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir faktora VIII variants ar B-domēna delēciju.4. The composition of claim 1, wherein the first agent is a variant of factor VIII with B domain deletion. 5. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir faktors IX.The composition of claim 1, wherein the first agent is factor IX. 6. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir von Villebranda (Von Willebrand) faktors.6. The composition of claim 1, wherein the first agent is a von Willebrand factor. 7. Kompozīcija saskaņā ar 1. punktu, kur otrais aģents ir kostimulējošās molekulas šķīstošā forma.The composition of claim 1, wherein the second agent is a soluble form of the costimulatory molecule. 8. Kompozīcija saskaņā ar 7. punktu, kur otrais aģents ir CTLA4 šķīstošā forma.The composition of claim 7, wherein the second agent is a CTLA4 soluble form. 9. Kompozīcija saskaņā ar 7. punktu, kur otrais aģents ir B7-1 šķīstošā forma, B7-2 šķīstošā forma vai minētās B7-1 šķīstošās formas un minētās B7-2The composition of claim 7, wherein the second agent is B7-1 soluble form, B7-2 soluble form, or said B7-1 soluble form and said B7-2 soluble form. 1 } šķīstošās formas kombinācija.1} soluble form combination. 10. Kompozīcija saskaņā ar 8. punktu, kur otrais aģents ir CTLA4lg.The composition of claim 8, wherein the second agent is CTLA4Ig. 11. Kompozīcija saskaņā ar 7. punktu, kur otrais aģents ir B7-1 Ig vai B7-2lg.The composition of claim 7, wherein the second agent is B7-1 Ig or B7-2lg. 12. Kompozīcija saskaņā ar 1. punktu, kur otrais aģents ir CD40 vai CD40L šķīstošā forma.The composition of claim 1, wherein the second agent is a CD40 or CD40L soluble form. 13. Kompozīcija saskaņā ar 1. punktu, kur otrais aģents ir antiviela, kas saistās pie kostimulējošās molekulas.13. The composition of claim 1, wherein the second agent is an antibody that binds to a costimulatory molecule. 14. Kompozīcija saskaņā ar 13. punktu, kur otrais aģents ir izvēlēts no grupas, kura sastāv no antivielas anti-B7-1, antivielas anti-B7-2 un no antivielas anti-B7-1 un antivielas anti-B7-2 kombinācijas.The composition of claim 13, wherein the second agent is selected from the group consisting of an anti-B7-1 antibody, an anti-B7-2 antibody, and a combination of an anti-B7-1 antibody and an anti-B7-2 antibody. 15. Kompozīcija saskaņā ar 13. punktu, kur antiviela ir antivielas anti-CD28 neaktivējošā forma.15. The composition of claim 13, wherein the antibody is a non-activating form of the anti-CD28 antibody. 16. Kompozīcijas izmantošana saskaņā ar jebkuru no 1. punkta līdz 15. punktam medikamenta pagatavošanai hemostatisku traucējumu ārstēšanai cilvēkam.Use of a composition according to any one of claims 1 to 15 for the manufacture of a medicament for the treatment of a hemostatic disorder in a human. 17. Izmantošana saskaņā ar 16. punktu, kur cilvēkam ir iepriekš eksistējoša imūnā reakcija uz pirmo aģentu.17. The use of claim 16, wherein the subject has a pre-existing immune response to the first agent. 18. Izmantošana saskaņā ar 16. punktu, kur cilvēkam nav iepriekš eksistējošas imūnās reakcijas uz pirmo aģentu.The use of claim 16, wherein the human has no pre-existing immune response to the first agent. 19. Izmantošana saskaņā ar 16. punktu, kur kompozīcija satur papildus imunosupresīvu aģentu.The use of claim 16, wherein the composition further comprises an immunosuppressive agent. 20. Izmantošana saskaņā ar 16. punktu, kur hemostatiskais traucējums ir izvēlēts no grupas, kurā ietilpst hemofīlija A, hemofīlija B, un von Villebranda (Von Willebrand) slimība.The use of claim 16, wherein the hemostatic disorder is selected from the group consisting of haemophilia A, haemophilia B, and von Willebrand's disease. 21. Kompozīcijas izmantošana medikamenta pagatavošanai hemostatisku traucējumu ārstēšanai cilvēkam, pie kam kompozīcija satur pirmo hemostāzi stimulējošo aģentu un otro aģentu, kas inhibē kostimulējošo signālu T šūnā, tādus, lai tiek novērsts hemostatiskais traucējums.Use of a composition for the manufacture of a medicament for the treatment of a hemostatic disorder in a human, wherein the composition comprises a first hemostatic stimulating agent and a second agent that inhibits a costimulatory signal in a T cell such as to prevent a hemostatic disorder. 22. Kompozīcijas izmantošana medikamenta pagatavošanai hemostatisku traucējumu ārstēšanai cilvēkam, pie kam kompozīcija satur pirmo hemostāzi stimulējošo aģentu un otro aģentu, kas inhibē kostimulējošo signālu T šūnā, tādus, lai tiek nomākta imūnā reakcija pret pirmo aģentu, līdz ar to ārstējot hemostatisko traucējumu.Use of a composition for the manufacture of a medicament for the treatment of a hemostatic disorder in a human, wherein the composition comprises a first hemostatic stimulating agent and a second agent that inhibits a costimulatory signal in a T cell such that an immune response to the first agent is suppressed. 23. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir faktors VIII.The use according to claim 21 or 22, wherein the first agent is factor VIII. 24. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir faktora VIII variants ar B-domēna delēciju.The use according to claim 21 or 22, wherein the first agent is a B-domain deletion of factor VIII. 25. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir faktors IX.The use according to claim 21 or 22, wherein the first agent is factor IX. 26. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir von Villebranda (Von Willebrand) faktors.Use according to claim 21 or 22, wherein the first agent is the von Willebrand factor. 27. Izmantošana saskaņā ar 21. vai 22. punktu, kur otrais aģents ir aģenta, kas T šūnai nodod kostimulējošo signālu, šķīstošā forma.The use of claim 21 or 22, wherein the second agent is a soluble form of an agent that transmits a costimulatory signal to a T cell. 28. Izmantošana saskaņā ar 27. punktu, kur aģents ir CTLA4 šķīstošā forma.The use of claim 27, wherein the agent is a CTLA4 soluble form. 29. Izmantošana saskaņā ar 28. punktu, kur aģents ir CTLA4lg.The use of claim 28, wherein the agent is CTLA4Ig. 30. Izmantošana saskaņā ar 27. punktu, kur aģents ir B7-1 šķīstošā forma, B72 šķīstošā forma vai B7-1 šķīstošās formas un B7-2 šķīstošās formas kombinācija.The use of claim 27, wherein the agent is a B7-1 soluble form, a B72 soluble form, or a combination of a B7-1 soluble form and a B7-2 soluble form. 31. Izmantošana saskaņā ar 30. punktu, kur aģents ir B7-1 Ig, B7-2lg vai abu B7-1 Ig un B7-2Ig kombinācija.The use of claim 30, wherein the agent is B7-1 Ig, B7-2lg, or a combination of both B7-1 Ig and B7-2Ig. 32. Izmantošana saskaņā ar 21. vai 22. punktu, kur otrais aģents ir antiviela, kas saistās pie kostimulējošās molekulas.The use of claim 21 or 22, wherein the second agent is an antibody that binds to a costimulatory molecule. 33. Izmantošana saskaņā ar 32. punktu, kur otrais aģents ir izvēlēts no grupas, kura sastāv no antivielas anti-B7-1, antivielas anti-B7-2 un no antivielu antiB7-1 un anti-B7-2 kombinācijas.The use of claim 32, wherein the second agent is selected from the group consisting of anti-B7-1 antibody, anti-B7-2 antibody, and a combination of antiB7-1 and anti-B7-2 antibodies. 34. Izmantošana saskaņā ar 32. punktu, kur antiviela ir antivielas anti-CD28 neaktivējošā forma.The use of claim 32, wherein the antibody is a non-activating form of the anti-CD28 antibody. 35. Izmantošana saskaņā ar 21. vai 22. punktu, kur hemostatiskais traucējums ir izvēlēts no grupas, kurā ietilpst hemofīlija A, hemofīlija B, un von Villebranda (Von Willebrand) slimība.Use according to claim 21 or 22, wherein the hemostatic disorder is selected from the group consisting of haemophilia A, haemophilia B, and von Willebrand's disease.
LVP-01-62A 1998-09-21 2001-04-20 METHOD FOR IMMUNE IMMUNE REACTION TO THERAPEUTIC PROTEINS LV12768B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (2)

Publication Number Publication Date
LV12768A LV12768A (en) 2001-12-20
LV12768B true LV12768B (en) 2002-06-20

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-01-62A LV12768B (en) 1998-09-21 2001-04-20 METHOD FOR IMMUNE IMMUNE REACTION TO THERAPEUTIC PROTEINS

Country Status (21)

Country Link
EP (1) EP1115423A1 (en)
JP (1) JP2002526455A (en)
KR (1) KR20010085830A (en)
CN (1) CN1331602A (en)
AU (1) AU761206B2 (en)
BR (1) BR9913991A (en)
CA (1) CA2343916A1 (en)
CZ (1) CZ20011021A3 (en)
EA (1) EA005236B1 (en)
HK (1) HK1039059A1 (en)
HU (1) HUP0103960A3 (en)
IL (1) IL142069A0 (en)
LT (1) LT4920B (en)
LV (1) LV12768B (en)
MX (1) MXPA01002898A (en)
NO (1) NO20011412L (en)
NZ (1) NZ511034A (en)
PL (1) PL346796A1 (en)
SI (1) SI20626A (en)
WO (1) WO2000016801A1 (en)
ZA (1) ZA200103156B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JP2003534291A (en) * 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
WO2005010483A2 (en) * 2003-06-10 2005-02-03 Smiths Detection Inc. Sensor arrangement
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (en) 1990-02-05 1994-09-02 Tm Innovation PROCESS FOR THE PREPARATION OF HUMAN FACTOR VIII AND FACTOR VIII ANALOGS.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
CA2110518C (en) 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
CA2200869A1 (en) * 1994-10-19 1996-05-02 Bruce C. Trapnell Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
JP4751493B2 (en) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Methods of blocking immune responses by blocking the GP39 / CD40 and CTLA4 / CD28 / B7 pathways and compositions used therefor
ATE356634T1 (en) * 1997-01-10 2007-04-15 Biogen Idec Inc METHOD FOR THERAPEUTIC ADMINISTRATION OF ANTI-CD40L AGENTS
AU733062B2 (en) * 1997-06-20 2001-05-03 Biogen Idec Ma Inc. CD154 blockade therapy for therapeutic protein inhibitor syndrome
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Also Published As

Publication number Publication date
AU6057899A (en) 2000-04-10
BR9913991A (en) 2001-07-03
NO20011412D0 (en) 2001-03-20
CA2343916A1 (en) 2000-03-30
LT4920B (en) 2002-06-25
HUP0103960A2 (en) 2002-02-28
PL346796A1 (en) 2002-02-25
AU761206B2 (en) 2003-05-29
WO2000016801A9 (en) 2000-10-26
KR20010085830A (en) 2001-09-07
CZ20011021A3 (en) 2001-10-17
JP2002526455A (en) 2002-08-20
HUP0103960A3 (en) 2003-09-29
EP1115423A1 (en) 2001-07-18
EA005236B1 (en) 2004-12-30
NO20011412L (en) 2001-05-16
LT2001045A (en) 2002-01-25
SI20626A (en) 2002-02-28
IL142069A0 (en) 2002-03-10
LV12768A (en) 2001-12-20
MXPA01002898A (en) 2002-06-04
EA200100385A1 (en) 2001-10-22
NZ511034A (en) 2004-03-26
WO2000016801A1 (en) 2000-03-30
CN1331602A (en) 2002-01-16
ZA200103156B (en) 2002-07-18
HK1039059A1 (en) 2002-04-12

Similar Documents

Publication Publication Date Title
Alon et al. TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein.
White II et al. A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A
Bidanset et al. Binding of the proteoglycan decorin to collagen type VI.
ES2136618T5 (en) HEALING OF WOUNDS.
CA2246352A1 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
TR199902194T2 (en) Substituted nitrogen-containing heterocycles as +p38 protein kinase inhibitors.
FR2714378B1 (en) Indol-2-one derivatives substituted in 3 with a nitrogen group, their preparation, pharmaceutical compositions containing them.
EP1806364A3 (en) New anti-IGF-IR antibodies and their applications
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
CA2221730A1 (en) Use of angiotensin ii type 2 receptor agonists in tissue repair
NZ332995A (en) A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
DE69435171D1 (en) PAN DR BINDEPROTEINS FOR INCREASING THE IMMUNE RESPONSE
DE60141043D1 (en) RECOMBINANT ANTI-CD30 ANTIBODIES AND THEIR USES
ATE324907T1 (en) COMPOUND AND MEDICINAL COMPOSITION FOR ADMINISTRATION OF ACTIVE INGREDIENTS
CA2247247A1 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
FI972703A0 (en) Recombinant IL-5 antagonists useful in the treatment of IL-5-related diseases
BR9811094A (en) Therapeutic agent for lymphatic tumors
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
CA2343579A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE59406938D1 (en) PHARMACEUTICAL PREPARATIONS WITH AN ACTIVE SUBSTANCE CONTAINING MODIFIED AMIDINE GROUPS
PL340465A1 (en) Antibodies against phosphorylated vasp (vasodilating agent stimulated phosphoprotein) hybridom cells for obtaining them and their application
ATE269865T1 (en) PYRAZOLO(3,4-G)QUINOXALINE AS PDGF RECEPTOR PROTEIN TYROSINE KINASE INHIBITORS
CA2233138A1 (en) Inhibitors of integrin receptors and their therapeutical uses
LV12768B (en) METHOD FOR IMMUNE IMMUNE REACTION TO THERAPEUTIC PROTEINS